{"filing":{"accession_number":"0001104659-26-086651","cik":"0000786947","ticker":null,"company_name":"ACURA PHARMACEUTICALS, INC","form":"8-K","filing_date":"2026-07-24","report_date":"2026-07-17","primary_document":"tm2621293d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465926086651/tm2621293d1_8k.htm"},"events":[{"id":20460,"run_id":18414,"accession_number":"0001104659-26-086651","anchor_item_number":"2.03","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Acura Pharmaceuticals entered into an amended consolidated secured promissory note with Abuse Deterrent Pharma, LLC on July 17, 2026, adding a $200,000 loan to bring total principal to approximately $10.9 million with accrued interest of ~$1.2 million. The company disclosed substantial going-concern risk, stating that absent additional financing by mid-August 2026, it will be forced to furlough/lay off employees, terminate operations, or seek bankruptcy protection.","company_name":"ACURA PHARMACEUTICALS, INC","ticker":null,"filing_date":"2026-07-24","form":"8-K","submitted_at":null,"items":[{"id":19821,"accession_number":"0001104659-26-086651","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses entry into a material definitive agreement involving a $200,000 loan from Abuse Deterrent Pharma, LLC on July 17, 2026, which is part of an amended consolidated secured promissory note now totaling $10,894,279 in principal with accrued interest of approximately $1,200,000. This represents creation of a direct financial obligation under Item 1.01. The materiality is underscored by the company's explicit statement that absent additional financing by mid-August 2026, it will be forced to furlough/lay off employees, terminate operations, or seek bankruptcy protection, indicating substantial going-concern risk tied directly to this debt structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T20:18:18.998465+00:00","company_name":"","ticker":null,"filing_date":""},{"id":19823,"accession_number":"0001104659-26-086651","item_number":"2.01","item_title":"Completion of Acquisition","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.72,"reasoning":"The 8-K Item 2.01 header indicates \"Completion of Acquisition or Disposition of Assets,\" but the actual disclosure is an amended loan schedule to a secured promissory note with Abuse Deterrent Pharma, LLC, showing cumulative principal of approximately $10.9 million as of July 17, 2026. This appears to be a financial obligation or credit facility amendment rather than an M\u0026A transaction. The exhibit documents ongoing loan advances rather than an asset acquisition or disposition, making this a financial event that does not fit the specific M\u0026A category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T20:18:18.998465+00:00","company_name":"","ticker":null,"filing_date":""},{"id":19824,"accession_number":"0001104659-26-086651","item_number":"2.03","item_title":"Creation of a Direct Financial","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses an amended loan schedule to a secured promissory note with Abuse Deterrent Pharma, LLC, documenting the creation and accumulation of direct financial obligations totaling approximately $10.9 million as of July 17, 2026. The Item 2.03 header explicitly identifies this as creation of a direct financial obligation, and the exhibit shows a series of loans (Loans #1 through #63) added to the original November 2022 note, with the most recent loan dated July 17, 2026. This represents the issuance and amendment of debt obligations material to the registrant's financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T20:18:18.998465+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19821,"accession_number":"0001104659-26-086651","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses entry into a material definitive agreement involving a $200,000 loan from Abuse Deterrent Pharma, LLC on July 17, 2026, which is part of an amended consolidated secured promissory note now totaling $10,894,279 in principal with accrued interest of approximately $1,200,000. This represents creation of a direct financial obligation under Item 1.01. The materiality is underscored by the company's explicit statement that absent additional financing by mid-August 2026, it will be forced to furlough/lay off employees, terminate operations, or seek bankruptcy protection, indicating substantial going-concern risk tied directly to this debt structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T20:18:18.998465+00:00","company_name":"ACURA PHARMACEUTICALS, INC","ticker":null,"filing_date":"2026-07-24"},{"id":19823,"accession_number":"0001104659-26-086651","item_number":"2.01","item_title":"Completion of Acquisition","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.72,"reasoning":"The 8-K Item 2.01 header indicates \"Completion of Acquisition or Disposition of Assets,\" but the actual disclosure is an amended loan schedule to a secured promissory note with Abuse Deterrent Pharma, LLC, showing cumulative principal of approximately $10.9 million as of July 17, 2026. This appears to be a financial obligation or credit facility amendment rather than an M\u0026A transaction. The exhibit documents ongoing loan advances rather than an asset acquisition or disposition, making this a financial event that does not fit the specific M\u0026A category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T20:18:18.998465+00:00","company_name":"ACURA PHARMACEUTICALS, INC","ticker":null,"filing_date":"2026-07-24"},{"id":19824,"accession_number":"0001104659-26-086651","item_number":"2.03","item_title":"Creation of a Direct Financial","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses an amended loan schedule to a secured promissory note with Abuse Deterrent Pharma, LLC, documenting the creation and accumulation of direct financial obligations totaling approximately $10.9 million as of July 17, 2026. The Item 2.03 header explicitly identifies this as creation of a direct financial obligation, and the exhibit shows a series of loans (Loans #1 through #63) added to the original November 2022 note, with the most recent loan dated July 17, 2026. This represents the issuance and amendment of debt obligations material to the registrant's financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T20:18:18.998465+00:00","company_name":"ACURA PHARMACEUTICALS, INC","ticker":null,"filing_date":"2026-07-24"}]}